Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.JAA.0000892832.09636.79 | DOI Listing |
J Int Assoc Provid AIDS Care
January 2025
Faculty of Health Sciences, Simon Fraser University, Vancouver BC, Canada.
In 2022, a community-academic collaborative team published 5 key recommendations for developing a national action plan to advance the sexual and reproductive health and rights (SRHR) of women living with HIV in Canada. In 2023, a national gathering was convened to strategize implementation of the recommendations across policy, practice, and research settings. Discussions highlighted that meaningful engagement of women living with HIV (recommendation 1) is foundational to implementing the other recommendations.
View Article and Find Full Text PDFEvid Based Nurs
January 2025
School of Nursing and Healthcare Leadership, University of Bradford, Bradford, UK.
JAAPA
January 2025
At the time this article was written, Noah Gadd, Whitney Wright, Jena Dooley, Hannah Stumbo, Emily Marshall, and Will Ewers were students in the PA program at the University of Kentucky in Lexington, Ky. Virginia L. Valentin is an associate professor and department chair in the PA program at the University of Kentucky. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Objective: To describe Kentucky's physician associate/assistant (PA) leadership pathway and provide advice for individual leadership trajectories.
Methods: A qualitative study using semistructured interviews and inductive coding methodology to identify themes of PA leaders.
Results: Participants were primarily female (76.
The purpose of this research is to describe the factors affecting hazardous chemotherapy exposure and strategies to foster chemotherapy safety among oncology nurses. Fifteen oncology nurses and 5 oncology nurse managers were recruited from 2 medical centers in the Midwest United States through convenience purposive sampling. A qualitative descriptive approach was employed.
View Article and Find Full Text PDFJTO Clin Res Rep
January 2025
Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Introduction: Osimertinib is now a standard first-line (1L) therapy for EGFR-mutated (EGFRm) advanced NSCLC. We aimed to characterize patterns of therapy and longitudinal risk of brain and liver metastasis in a cohort of EGFRm NSCLC.
Methods: Patients with metastatic EGFRm NSCLC who received 1L systemic therapy at sites within the Academic Thoracic Medical Investigator's Consortium were included; demographic and clinical data including treatment patterns were described.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!